Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
Rhea-AI Summary
Virax Biolabs (NASDAQ:VRAX), a biotechnology company specializing in viral disease diagnostics, has appointed Dr. Iain Miller as an Independent Director effective July 29, 2025. Dr. Miller, who replaces outgoing director Yair Erez, brings over 30 years of leadership experience in diagnostics and MedTech sectors.
Dr. Miller's extensive background includes senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has founded four MedTech companies and served as CEO of Presymptom Health, where he developed InfectiClear®. His expertise spans commercial, technical, and regulatory domains, with experience serving on the UK's NICE Technology Appraisal Committee and contributing to NHS England and MHRA innovation programs.
Positive
- Appointment of highly qualified director with 30+ years of diagnostics and MedTech experience
- Addition of valuable regulatory expertise through Dr. Miller's experience with NICE, NHS England, and MHRA
- Strategic strengthening of leadership team during company's expansion phase
Negative
- Loss of existing board member Yair Erez
News Market Reaction
On the day this news was published, VRAX declined 2.73%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $121K from the company's valuation, bringing the market cap to $4M at that time.
Data tracked by StockTitan Argus on the day of publication.
Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable service and contributions.
Dr. Miller brings over 30 years of leadership experience across the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has worked extensively across both the
Dr. Miller has also served on the
"We are pleased to welcome Iain Miller, PhD to the Virax Board during this important phase of development," said James Foster, Chief Executive Officer of Virax Biolabs. "His leadership across private and public sector organisations, combined with deep diagnostics expertise and international experience, will be instrumental as we work to advance our immune profiling platform — building on our initial Research-Use-Only (RUO) product rollout and progressing toward IVD development, regulatory engagement, and future market entry."
Dr. Miller commented: "I am excited to join the Board of Virax Biolabs at a time of strategic focus and momentum. The Company's immune profiling platform presents a compelling opportunity to enhance how chronic and post-viral conditions are monitored. I look forward to supporting the team in realising this vision."
About Virax Biolabs Group Limited.
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-appoints-iain-miller-phd-as-independent-director-to-accelerate-commercial-strategy-302515923.html
SOURCE Virax BioLabs Group Limited
FAQ
Who is the new Independent Director of Virax Biolabs (NASDAQ:VRAX)?
What is Dr. Iain Miller's background and experience before joining Virax Biolabs?
How will Dr. Miller's appointment benefit Virax Biolabs' strategy?
Who did Dr. Iain Miller replace on Virax Biolabs' Board of Directors?
What are Dr. Iain Miller's academic qualifications?
